Results 181 to 190 of about 3,675 (259)

DNA coronas resist nuclease degradation. [PDF]

open access: yesBiophys J
Anees F   +5 more
europepmc   +1 more source

A Self‐Driving Lab for Solution‐Processed Electrochromic Thin Films

open access: yesAdvanced Intelligent Systems, EarlyView.
A self‐driving laboratory accelerates the development of solution‐processed electrochromic thin films. By coupling machine learning with robotic fabrication and characterization, this closed‐loop platform systematically navigates complex processing parameters.
Selma Dahms   +7 more
wiley   +1 more source

Inflammatory disease progression shapes nanoparticle biomolecular corona-mediated immune activation profiles. [PDF]

open access: yesNat Commun
Shaw JR   +9 more
europepmc   +1 more source

AI‐Assisted IoT‐Enabled ECG Monitoring: Integrating Foundational and Generative AI Tools for Sustainable Smart Healthcare—Recent Trends

open access: yesAI &Innovation, EarlyView.
ABSTRACT The rapid evolution of the Internet of Things (IoT) has significantly advanced the field of electrocardiogram (ECG) monitoring, enabling real‐time, remote, and patient‐centric cardiac care. This paper presents a comprehensive survey of AI assisted IoT‐based ECG monitoring systems, focusing on the integration of emerging technologies such as ...
Amrita Choudhury   +2 more
wiley   +1 more source

Profiling Glycoproteins Enriched by Multinanoparticle Protein Corona. [PDF]

open access: yesAnal Chem
Sutherland E   +4 more
europepmc   +1 more source

Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack   +25 more
wiley   +1 more source

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and ...
Murali Janakiram   +94 more
wiley   +1 more source

Home - About - Disclaimer - Privacy